Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. (July 2016)

• Record Type: Journal Article
• Authors: Xie, Fangyuan; Zhang, Siyue; Liu, Junjie; Gong, Zhirong; Yang, Kaixuan; Zhang, He; Lu, Ying; Zou, Hao; Yu, Yuan; Chen, Yan; Sun, Zhiguo; Wang, Xinxia; Zhang, Hai; Zhang, Guoqing; Li, Wei; Li, Bohua; Gao, Jie; Zhong, Yanqiang
• Is Part Of: Nanomedicine. Volume 11:Number 14(2016)
• Page Start: 1831
• Page End: 1846
• Publication Date: 2016-07
• Subjects: autophagy -- cancer stem cells -- chloroquine -- combined therapy -- liposomes -- liver cancer -- salinomycin; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2016-0125
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To improve the suboptimal therapeutic efficacy of salinomycin (SAL) toward liver cancer cells using chloroquine (CQ) combination by the liposomes co-delivering SAL and CQ (SCNL).Materials & methods: The synergy of these two drugs was evaluated in liver cancer cells (HepG2) and liver cancer stem cells (LCSCs) by median-effect analysis. SCNL with optimized ratio were developed. The cytotoxic effect and basal autophagy flux (measure of autophagic degradation activity) of various formulations were evaluated.Results & conclusion: CQ could significantly increase the cytotoxic effect of SAL in HepG2 cells, but not in HepG2-LCSCs, due to the greater basal autophagy flux in HepG2 cells. This combination therapy is promising for liver cancer treatment by eradicating liver cancer cells and LCSCs.